Teeple A, Muser E. Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis. J of Skin [Internet]. 2018 Dec. 17 [cited 2024 Jul. 3];2:S80. Available from: https://jofskin.org/33014/index.php/skin/article/view/477